An Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly str...

Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufact...

The government is expected to extend the deadline for small drug companies to comply with the revised Schedule M standards until December 3...

The govt may extend the deadline for drug manufacturers to comply with revised Schedule M standards until December 2025. A final notificati...

The health ministry has sought a legal opinion on extending the deadline for MSMEs to comply with revised Schedule M standards. The final d...

Pharma lobby group FOPE has requested the government to extend the compliance deadline for the revised Schedule M till December 31, 2026. T...

The government is set to decide on implementing the revised Schedule M for pharmaceutical products by next week. While pharma groups have r...

Schedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a ...

India’s FoPE seeks a 10-year exemption for patented and low-cost drugs from price controls. Requests include DPCO and 12% GST adjustments d...

In a significant development, a five-member expert committee has been appointed to assess the feasibility of allowing the manufacturing of ...

In a recent diktat, the government said action will be taken against pharma units that are flouting the norms by manufacturing nutraceutica...

FOPE said that the manufactures follow the rules as laid down in the DPCO, 2013. At the same time, manufacturers look to NPPA to fix the pr...

Raw materials from China are used in making antibiotics, paracetamol, and diabetes and cardiovascular drugs, among others. Companies includ...

The HC asked the government whether it needed to consider the validity of licences held by pharma companies producing the combination drugs...